• Most Popular
  • Most Shared

Merck. Dynavax in hepatitis B vaccine deal

Thu Nov 1, 2007 7:47am EDT

Stocks

   

NEW YORK, Nov 1 (Reuters) - Merck & Co. (MRK.N) and Dynavax Technologies (DVAX.O) said on Thursday they agreed to jointly develop an experimental hepatitis B vaccine, which is in late-stage clinical trials.

Mergers & Acquisitions

In the deal, Merck receives worldwide rights to the vaccine, Heplisav, and will fund vaccine development and be responsible for commercialization.

Dynavax will receive an initial payment of $31.5 million, and will be eligible to receive up to $105 million in payments should the product reach various development and sales milestones, as well as royalties. (Reporting by Lewis Krauskopf)

Mergers & Acquisitions


More from Reuters

Photo

Jobless claims hit 17-month low

WASHINGTON (Reuters) - The number of U.S. workers filing new applications for jobless benefits unexpectedly fell last week to the lowest level in about 17 months, suggesting the economy might be on the cusp of job creation.

» More Top News
A picture of an arrow in this file photo. REUTERS/File
OUTLOOK 2010:

The coming Great Inflation

Real or imagined, Americans have plenty of things to worry about. Should inflation be one of them?  Full Article 

ECONOMY
People walk past a branch of Bank of America in New York's financial district April 28, 2009. REUTERS/Brendan McDermid
Rolfe Winkler:

Move your money

Boycotting "too big to fail" banks is a great idea -- so long as investors remember that banks aren't the only ones responsible for the crisis.  Full Article 

    Commentary